Results 61 to 70 of about 58,451 (152)
Background Evidence suggests differences in clinical characteristics, causes, and prognoses between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Tin‐Kwang Lin +6 more
doaj +1 more source
Background: Although central apneas (CA) and obstructive apneas (OA) are highly prevalent in heart failure (HF), a comparison of apnea prevalence, predictors and clinical correlates in the whole HF spectrum, including HF with reduced ejection fraction ...
Chiara Borrelli +17 more
doaj +1 more source
Obesity and heart failure with preserved ejection fraction
Aim: To perform an overall assessment of heart failure with preserved ejection fraction (HFpEF) adults with central obesity. Materials and Methods: We enrolled HFpEF patients with central obesity (n =73, mean age 52.4 } 6.3 years) and without obesity (n =70, mean age 51.9 } 7.1 years) and compared with an age-matched healthy subjects who had not ...
Tetyana M, Ternushchak +5 more
openaire +2 more sources
Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have symptoms and signs of HF with normal or near-normal left ventricular ejection fraction (LVEF ≥50%).
Chao Ma +4 more
doaj +1 more source
Cardiorenal Syndrome Caused by Heart Failure with Preserved Ejection Fraction
Since cardiorenal dysfunction is usually secondary to multiple factors acting in concert (and not only reduced cardiac output) in the present paper we are going to focus on the interrelationship between heart failure with normal ejection fraction and the
Chiara Lazzeri +3 more
doaj +1 more source
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Heerspink, Hiddo J.L. +2 more
openaire +6 more sources
Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
Heart failure with preserved ejection fraction (HFpEF) remains a significant challenge in modern healthcare. It accounts for the majority of heart failure cases and their number worldwide is steadily increasing.
Ekaterina Ogurtsova +4 more
doaj +1 more source
Background Empagliflozin, a member of the Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor family, is a promising antidiabetic drug with proven benefits in heart failure (HF). However, its effects in heart failure patients in varying ejection fractions
Shahjada Selim +15 more
doaj +1 more source
Semaglutide in Heart Failure With Preserved Ejection Fraction
Kamil A. Kobak, PhD, Ying Ann Chiao, PhD
doaj +1 more source
Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction. [PDF]
Adeli A +7 more
europepmc +1 more source

